Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Q BioMed Inc. (OTC: QBIO).

Full DD Report for QBIO

You must become a subscriber to view this report.


Recent News from (OTC: QBIO)

Q BioMed Inc. Announces FDA Filing for Strontium Chloride Sr89 Injection USP for Relief of Metastatic Cancer Bone Pain
NEW YORK , Aug. 20, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) (OtherOTC: QBIO), a commercial stage biotechnology acceleration development company, and BioNucleonics, licensor of Strontium 89 Chloride, announce submission of a supplemental regulatory filing to the FDA for the app...
Source: PR Newswire
Date: August, 20 2018 09:29
Q Biomed Inc. Extends its Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma and Initiates a Clinical Study
NEW YORK , July 25, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that it is extending its option agreement with Washington University in St. Louis . Under the agreement granting the exclusi...
Source: PR Newswire
Date: July, 25 2018 08:30
Q BioMed Inc. Provides Important Update on Mannin Research Tie2 Technology Platform Development
NEW YORK , June 6, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, provides the following update on its exclusively licensed platform technology asset from Mannin Research Inc. Together with Mannin Research, the...
Source: PR Newswire
Date: June, 06 2018 08:30
Q BioMed Inc Places 2nd in Company Category for Autism Speaks Walk Fundraiser
NEW YORK , June 1, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, placed second in the 'company category' at this year's Bay Area Autism Speaks Walk. The fundraiser provided Q BioMed an opportunity to connect with and better understand the autism...
Source: PR Newswire
Date: June, 01 2018 08:00
Q Biomed Inc. to Present at the Microcap Conference Taking Place April 9-10 at the Essex House in New York City
NEW YORK , April 5, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin , Chief Executive Officer, will present at the MicroCap Conference being held at the Essex House in New York City , on Tuesday ...
Source: PR Newswire
Date: April, 05 2018 08:00
Significant Progress in Non-Opioid Therapy Picks up Steam As Market Projected to Reach $22 Billion by 2022
Palm Beach, FL – (March 16, 2018) – According to BCC Research Report , the global market for non-opioid pain treatment totaled $9.9 billion in 2017 and is estimated to reach $22.6 billion by 2022, growing at a compound annual growth rate (CAGR) of 18.0% for the period of 2017-2022...
Source: MarketNewsUpdates.com
Date: March, 16 2018 09:05
Q Biomed Inc. Announces FDA Filing for Approval of a New Manufacturing Facility for Non-Opioid Strontium Chloride SR89 Injection USP for Relief of Cancer Bone Pain
NEW YORK , March 16, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, and Bio-Nucleonics, licensor of Strontium 89 Chloride, announce submission of a regulatory filing to the FDA for the approval of a new manufacturing ...
Source: PR Newswire
Date: March, 16 2018 08:30
Q BioMed Inc. to Present at 30th Annual Roth Conference, Taking Place March 11-14, 2018, in Dana Point, CA
NEW YORK , March 9, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin , Chief Executive Officer will present at the 30th Annual Roth Conference, being held at the Ritz Carlton in Dana Point, Califo...
Source: PR Newswire
Date: March, 09 2018 15:01
OTCQX And OTCQB Companies to Present At 2018 ROTH Conference
NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today unveiled the list of OTCQX® Best Market and OTCQB® Venture Market presenting companies at the 30 th Annual ROTH Confe...
Source: PR Newswire
Date: March, 08 2018 10:00
The Story Behind Growth: New Report Discusses CytoDyn Inc. and Q Biomed Inc. - Emerging Trends Within New Industry
NEW YORK, NY / ACCESSWIRE / February 2 2 , 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of CytoDyn Inc. (OTCQB: CYDY ) and Q Biomed Inc. (OTCQB: QBIO ), including recent technical analysis and consolidated fundamental information. Gro...
Source: ACCESSWIRE IA
Date: February, 22 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-121.781.761.791.7454,610
2018-12-111.811.741.811.70142,300
2018-12-101.891.8121.891.7078,413
2018-12-071.861.8751.901.8233,828
2018-12-061.921.831.951.8273,855

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1232,18854,61058.9416Short
2018-12-1120,78842,30049.1442Short
2018-12-1022,27478,41328.4060Cover
2018-12-0716,65533,82849.2344Short
2018-12-0619,82072,85527.2047Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on QBIO.


About Q BioMed Inc. (OTC: QBIO)

Logo for Q BioMed Inc. (OTC: QBIO)

Q BioMed Inc. Q is a biomedical acceleration and development company focused on acquiring companies and biomedical assets in clinical stage or and near revenue development. Q is dedicated to providing these target companies strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.

 

Contact Information

 

 

Current Management

  • Denis Corin / President, Consultant
  • Ari Jatwes / Business Analyst
  • Denis Corin /
  • Riccardo Panicucci /
  • William S. Rosenstadt /

Current Share Structure

  • Market Cap: $41,564,396 - 03/15/2018
  • Authorized: 250,000,000 - 03/01/2018
  • Issue and Outstanding: 13,947,784 - 03/01/2018
  • Float: 4,999,835 - 11/30/2016

 


Recent Filings from (OTC: QBIO)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 02 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: January, 31 2018
Amendment to general form for registration of securities under the Securities Act of 1933
Filing Type: S-1/AFiling Source: edgar
Filing Date: January, 12 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: January, 12 2018
Amendment to general form for registration of securities under the Securities Act of 1933
Filing Type: S-1/AFiling Source: edgar
Filing Date: January, 10 2018
Amendment to general form for registration of securities under the Securities Act of 1933
Filing Type: S-1/AFiling Source: edgar
Filing Date: December, 22 2017
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: December, 12 2017

 

 


Daily Technical Chart for (OTC: QBIO)

Daily Technical Chart for (OTC: QBIO)


Stay tuned for daily updates and more on (OTC: QBIO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: QBIO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in QBIO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of QBIO and does not buy, sell, or trade any shares of QBIO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/